Biocon is currently trading at Rs. 314.30, up by 0.45 points or 0.14% from its previous closing of Rs. 313.70 on the BSE.
The scrip opened at Rs. 316.80 and has touched a high and low of Rs. 317.35 and Rs. 314.30 respectively. So far 15425 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 414.30 on 19-Jul-2021 and a 52 week low of Rs. 305.00 on 01-Jul-2022.
Last one week high and low of the scrip stood at Rs. 317.35 and Rs. 305.00 respectively. The current market cap of the company is Rs. 37662.82 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.98% and 15.39% respectively.
Biocon’s subsidiary — Biocon Biologics has received EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.
The facility, spread across 340,000-square feet, will enhance capabilities manifold to manufacture drug substance of mAbs portfolio and will enable to serve patients across the globe. This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing. Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE)
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.